User contributions
From OncoWiki
(newest | oldest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
- 05:22, 27 August 2018 (diff | hist) . . (+1,614) . . SMILE (current)
- 01:44, 27 August 2018 (diff | hist) . . (+10) . . m Lymphoma Hodgkin's, Adult (→Frontline) (current)
- 13:06, 14 June 2017 (diff | hist) . . (+931) . . N BeGeV (Created page with "== Hodgkin disease == salvage regimen in relapsed Hodgkin's lymphoma == Regimen == phase II study * Gemcitabine 800 mg/m2 on days 1 and 4 * Vinorelbine 20 mg/m2 on day 1, *...") (current)
- 12:57, 14 June 2017 (diff | hist) . . (+14) . . Lymphoma Hodgkin's, Adult (→Salvage)
- 02:03, 21 September 2016 (diff | hist) . . (+593) . . Flu Bu ATG - Slavin (current)
- 02:02, 21 September 2016 (diff | hist) . . (+316) . . N Flu Bu ATG - Slavin (Created page with "*Fludarabine (Fludara) 30 mg/m<sup>2</sup> IV once per day on days -10 to -5 (6 consecutive days) *Busulfan (Myleran) 4 mg/kg/day PO on days -6 to -5 (2 consecutive da...")
- 01:55, 21 September 2016 (diff | hist) . . (+1) . . m Stem Cell Transplantation (→Non-myeloablative conditioning regimens) (current)
- 01:54, 21 September 2016 (diff | hist) . . (+23) . . Stem Cell Transplantation (→Non-myeloablative conditioning regimens)
- 20:21, 6 July 2016 (diff | hist) . . (+2,303) . . N Flu Bu ATG for Haplo (Created page with "== Regimen == *Busulfan (Busulfex, Otsuka Pharmaceuticals) 3.2 mg/kg per day intravenously on days −7 and −6 *Fludarabine 30 mg/m2 per day intravenously on days −7 to...") (current)
- 20:07, 6 July 2016 (diff | hist) . . (+1) . . m Stem Cell Transplantation (→Non-myeloablative conditioning regimens)
- 20:06, 6 July 2016 (diff | hist) . . (+25) . . Stem Cell Transplantation (→Non-myeloablative conditioning regimens)
- 21:52, 16 May 2016 (diff | hist) . . (+1,666) . . N R-MPV (Created page with "== Regimen == IV Rituximab 500 mg/m2 day 1 IV Methotrexate 3.5 mg/m2 (over 2hours) day 2 IV Vincristine 1.4 mg/m2 (capped at 2.8mg)day 2 Procarbazine 100 mg/m2 /day was gi...") (current)
- 21:45, 16 May 2016 (diff | hist) . . (+4) . . m Lymphoma Non-Hodgkin's, Adult (→Primary CNS Lymphoma) (current)
- 21:44, 16 May 2016 (diff | hist) . . (+10) . . Lymphoma Non-Hodgkin's, Adult (→Primary CNS Lymphoma)
- 02:18, 18 April 2016 (diff | hist) . . (+1,734) . . N VDT-PACE (VDTPACE) (current)
- 01:50, 18 April 2016 (diff | hist) . . (+1) . . m Multiple Myeloma And Plasma Cell Dyscrasias (→Combinations) (current)
- 01:50, 18 April 2016 (diff | hist) . . (+13) . . m Multiple Myeloma And Plasma Cell Dyscrasias
- 22:01, 1 May 2014 (diff | hist) . . (+35) . . m Lymphoma Non-Hodgkin's, Adult (→Aggressive NHL)
- 21:54, 1 May 2014 (diff | hist) . . (+113) . . m Brentuximab vedotin (→Brentuximab vedotin (Adcetris)) (current)
- 21:53, 1 May 2014 (diff | hist) . . (+1,048) . . m Brentuximab vedotin (→Regimen)
- 21:50, 1 May 2014 (diff | hist) . . (+334) . . N Brentuximab vedotin (Created page with "==Brentuximab vedotin (Adcetris)== ===Regimen=== *Brentuximab vedotin (Adcetris) 1.8 mg/kg IV over 30 minutes on day 1 Supportive medications: *Rothe et al. 2012: "no p...")
- 21:49, 1 May 2014 (diff | hist) . . (+28) . . m Lymphoma Hodgkin's, Adult (→Salvage)
- 03:36, 30 October 2013 (diff | hist) . . (-25) . . m Adrenocortical Carcinoma (current)
- 03:35, 30 October 2013 (diff | hist) . . (+25) . . m Adrenocortical Carcinoma
- 03:16, 30 October 2013 (diff | hist) . . (+52) . . m Adrenocortical Carcinoma (→References)
- 03:13, 30 October 2013 (diff | hist) . . (-61) . . m Adrenocortical Carcinoma (→References)
- 03:12, 30 October 2013 (diff | hist) . . (+127) . . m Adrenocortical Carcinoma (→References)
- 03:10, 30 October 2013 (diff | hist) . . (+879) . . m Adrenocortical Carcinoma (→References)
- 03:07, 30 October 2013 (diff | hist) . . (+344) . . m Adrenocortical Carcinoma
- 03:01, 30 October 2013 (diff | hist) . . (+128) . . m Adrenocortical Carcinoma
- 02:44, 30 October 2013 (diff | hist) . . (+822) . . Adrenocortical Carcinoma (→Adrenal gland tumors, adrenocortical carcinoma - adjuvant therapy)
- 02:43, 30 October 2013 (diff | hist) . . (+803) . . m Adrenocortical Carcinoma (→Adrenal gland tumors, adrenocortical carcinoma - adjuvant therapy)
- 02:41, 30 October 2013 (diff | hist) . . (+67) . . N Adrenocortical Carcinoma (Created page with "=Adrenal gland tumors, adrenocortical carcinoma - adjuvant therapy=")
- 02:34, 30 October 2013 (diff | hist) . . (+642) . . N OncoWiki:General disclaimer (Created page with "Information on this website is meant only for Healthcare Practitioners. Use of any information obtained from this website is entirely at the user's discretion. You are advised...") (current)
- 02:34, 30 October 2013 (diff | hist) . . (+192) . . N OncoWiki:About (Created page with "This site will serve as a free repository for oncology information, chemotherapy protocols and cancer treatment regimens and is meant for Healthcare providers working in the f...") (current)
- 09:46, 26 October 2013 (diff | hist) . . (+26) . . Main Page (current)
- 07:28, 29 August 2013 (diff | hist) . . (+5) . . m EPOCH-DA (→References) (current)
- 07:21, 29 August 2013 (diff | hist) . . (+759) . . m EPOCH-DA
- 07:20, 29 August 2013 (diff | hist) . . (+20) . . m EPOCH-DA (→Dose adjustments)
- 07:19, 29 August 2013 (diff | hist) . . (+405) . . m EPOCH-DA
- 07:18, 29 August 2013 (diff | hist) . . (+5) . . m EPOCH-DA (→Supportive medications)
- 07:16, 29 August 2013 (diff | hist) . . (+5) . . m EPOCH-DA (→Supportive medications)
- 07:16, 29 August 2013 (diff | hist) . . (+117) . . m EPOCH-DA (→Supportive medications)
- 07:15, 29 August 2013 (diff | hist) . . (+113) . . m EPOCH-DA (→Supportive medications)
- 07:15, 29 August 2013 (diff | hist) . . (+31) . . EPOCH-DA (→Regimen)
- 07:14, 29 August 2013 (diff | hist) . . (+32) . . m EPOCH-DA (→Regimen)
- 07:14, 29 August 2013 (diff | hist) . . (+169) . . m EPOCH-DA (→Regimen)
- 07:13, 29 August 2013 (diff | hist) . . (+114) . . m EPOCH-DA (→Regimen)
- 07:05, 29 August 2013 (diff | hist) . . (+45) . . m EPOCH-DA (→Regimen)
- 07:04, 29 August 2013 (diff | hist) . . (+110) . . m EPOCH-DA (→Regimen)
(newest | oldest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
